Argenica Therapeutics Ltd: Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
Argenica Therapeutics Ltd: Appendix 4G & Corporate Governance Statement
Argenica Therapeutics Ltd: Appendix 4E & Annual Report to 30 June 2024
Argenica Therapeutics Ltd: Change of Director's Interest Notice
Argenica Therapeutics Ltd: Notification regarding unquoted securities - AGN
Argenica Therapeutics Ltd: Results of Meeting
Argenica Therapeutics Ltd: Change of Director's Interest Notice x3
Argenica Therapeutics Ltd: Cleansing Notice
Argenica Therapeutics Ltd: Notification of cessation of securities - AGN
Argenica Therapeutics Ltd: Application for quotation of securities - AGN
Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Ltd: Phase 2 Stroke Clinical Trial Update
Argenica Therapeutics Ltd: Investor Webinar Presentation
Argenica Therapeutics Ltd: Investor Presentation
Argenica Therapeutics Ltd: Notice of General Meeting/Proxy Form
Argenica Therapeutics Ltd: Notice of initial substantial holder from IFL
Argenica Therapeutics Ltd: Cleansing Notice
Argenica Therapeutics Ltd: Notification of cessation of securities - AGN
Argenica Therapeutics Ltd: Application for quotation of securities - AGN
Argenica Therapeutics Ltd: Notification of cessation of securities - AGN
No Data